STING, SUMO In Spotlight As Takeda Showcases Oncology Progress
Japanese firm points to progress in its cancer pipeline as it looks to launch three new molecular entities in the sector by 2024 and investigates novel modalities.
You may also be interested in...
From a STING agonist to a SOS1 inhibitor, Lupin listed oncology candidates from the preclinical stage to those in IND-enabling studies during the recently concluded J.P. Morgan conference. Meanwhile, the newly spun-off oncology subsidiary awaits partners.
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
The Japanese pharma held its first investor day in New York, outlining the company's strategy to deliver long-term growth through a newly energized oncology, gastrointestinal and rare disease pipeline.